• Higher adherence to antiretroviral therapy (ART) for patients with human immunodeficiency virus (HIV) is associated with improved clinical outcomes, including decreased viral load, delayed progression to acquired immune deficiency syndrome (AIDS) and even decreased mortality.
• Previously reported rates of adherence to ART vary widely depending on study methodology, geographic location, and patient population.
• In a worldwide meta-analysis of 84 observational studies, only 62% of adults with HIV achieved adherence of at least 90% to ART.
What is already known about this subject
• This study adds to the current understanding of real-world antiretroviral regimens as well as patient adherence to ART in more recent years (2010-2011).
• Only 67.4% of patients on ART were on U.S. Department of Health and Human Services (HHS)-recommended antiretroviral combinations, while 1.2% of patients were on contraindicated therapies and 31.4% of patients were on other regimens that were not listed as recommended or contraindicated.
• Mean adherence to HHS-recommended ART regimens, as calculated by medication possession ratio (MPR), was 91.5% ± 14.0, with 73.1% of patients having achieved MPR ≥ 90%.
• Patients on a single-tablet regimen (STR) were 1.3 times more likely to achieve adherence of at least 90%, as measured by MPR.
classified as "Not Recommended"; all other regimens were classified as "Other." For patients receiving antiretroviral regimens classified as "Recommended," medication adherence was analyzed for 1 year after the end of the 120-day window in which the antiretroviral regimen was defined. The University of Maryland Institutional Review Board approved the research protocol.
Primary Outcome
The primary outcome was to evaluate adherence to antiretroviral regimens as assessed by MPR in patients receiving HHSrecommended regimens. MPR was first calculated for each patient's individual antiretroviral product as the ratio of the sum of the days supply of the prescription filled by the patient divided by the number of days from the fill date of the index prescription to the last fill date plus the days supply for the final prescription fill. MPR was cut off at 1 for patients with higher than 100% adherence.
The overall antiretroviral regimen MPR for each patient was then calculated based on the weighted window of use for each individual ART product. For example, if a patient was on drug A for 6 months with an MPR = 0.8, drug B for 3 months with an MPR = 0.4, and drug C for 12 months with an MPR = 0.9, the mean MPR was calculated to be [(0.8 × 6=4.8) + (0.4 × 3 = 1.2) + (0.9 × 12 = 10.8)] = 16.8/21 = 0.8. MPR for the ART regimen was then assessed as a categorical variable using the threshold adherence of ≥ 90%. Adherence was defined as MPR ≥ 90% while MPR < 90% signified poor adherence.
In the pharmacy claims database, there were both positive and negative (reversed) claims. Pharmacists generate a positive claim when prescription information is submitted to the MCO for adjudication, and a negative claim occurs when the claim is reversed. Reasons for negative claims include an error in the submission of the electronic claim and if the member does not pick up the prescription. All positive and negative matched claim duplicates were deleted to ensure that only prescriptions received by members were included in the data used in this study. For patients with changes to their index antiretroviral regimens, MPR was assessed only during the period of the index regimen.
Secondary Outcome
The secondary outcome was to explore factors associated with adherence to ART (i.e., MPR ≥ 90%) in patients receiving HHSrecommended regimens. These factors included age, sex, type of health insurance coverage, number of outpatient visits, number of hospitalizations, and the use of STRs. The frequency of resource utilization (i.e., number of outpatient visits and hospitalizations) and cost of care (including inpatient, outpatient, and pharmacy costs) were obtained during the 12 months after the 120-day window and compared. measured by medication possession ratio (MPR), has been found to be associated with lower CD4 counts, increased viral load, and decreased mortality. This study assesses real-world adherence to ART in recent years in the United States using retrospective pharmacy claims from a managed care organization (MCO). Medication adherence, as measured by MPR, is reported, along with factors associated with being adherent, defined as MPR ≥ 90%, to a particular ART regimen. In patients with at least 1 antiretroviral claim during the 120-day window and 1 antiretroviral claim within 12 months after the 120-day window, an index regimen during the 120-day window was defined to include the total number of antiretroviral products (i.e., marketed formulations), the use of combination products (i.e., products containing 2 or more single antiretroviral agents), and the use of single-tablet regimens (STR; i.e., once-a-day regimen). Each patient's antiretroviral regimen was also classified based upon the U.S. Department of Health and Human Services (HHS) 2011 Antiretroviral Guidelines. 1 HHS "preferred," "alternative," and "acceptable" regimens for treatment naïve patients were classified as "Recommended"; HHS regimens "not recommended" for initial therapy were
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Statistical Analysis
Descriptive statistics were reported for sociodemographic and clinical characteristics of the cohort. Patient characteristics were measured at the index date and included age, sex, and type of health plan. For the primary outcome, mean MPR as well as percentage of patients with MPR ≥ 90% were reported.
For the secondary outcome, univariate analyses examined the association between each factor (sex; age; type of health plan; use of STR; number of outpatient visits; number of hospitalizations; and the cost of inpatient, outpatient, and pharmacy care) and adherence (MPR ≥ 90%). Significant factors from univariate analyses were included in a binomial logistic regression model to determine predictors of achieving MPR ≥ 90%. Statistical significance was defined as P ≤ 0.05.
■■ Results
A total of 4,547 adult members were considered to have HIV ( Figure 1 ). The mean age was 43.3 ± 10.2 years, and less than 1% of patients were over 65 years. The majority were male (73.6%), and 55.2% were enrolled in a health management organization (HMO) plan. Over one fifth of the cohort (22.4%; 1,019/4,547) had no antiretroviral claim during the 120-day window of ART establishment.
For the 3,528 patients who received ART, the mean (standard deviation [SD]) number of unique drug products was 2.2 ± 1.1 antiretroviral drugs per member with a range of 1 to 6 products. A total of 3,085 (87.4%) patients used combination products, defined as 2 or more drugs within 1 dosage form. Among those using combination products, 39.2% (1,208/3,085) were on STRs. Patients may have been receiving another ART product in addition to the STR.
About two thirds (67.4%; 2,377/3,528) of patients were on HHS "Recommended" regimens, about one third (31.4%; 1,107/3,528) were on "Other" regimens, and 1.2% (44/3,528) of patients received regimens "Not Recommended" by HHS. The use of combination products and the mean number of unique antiretroviral products differed depending on whether the ART regimen was "Recommended," "Not Recommended," or "Other" according to HHS 2011 Guidelines (Table 1) . Almost half (47.8%; 1,136/2,377) of patients under HHS "Recommended" therapy were receiving STR.
For ART regimens classified as "Recommended" by HHS, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (56.6%) were most common, followed by boostedprotease inhibitor (PI) regimens (34.2%). There was little use of chemokin C-C motif receptor 5 (CCR5) inhibitors (0.3%), integrase inhibitors (6.4%), or unboosted-PI regimens (2.4%).
Of the 2,377 patients on HHS "Recommended" regimens, the mean age was 42.8 years with very few patients older than 65 years (0.7%; Table 2 ). The majority of patients were male (73.8%) and over half were enrolled in an HMO plan (57.7%). The mean number of outpatient visits was 3.1 visits per patient per year (PPPY), and the mean number of hospitalizations was 0.5 PPPY. The mean total health care costs (inpatient + outpatient + pharmacy) were $18,382 PPPY, of which pharmacy costs comprised 86%. Pharmacy costs for ART and non-ART prescriptions were $13,906 PPPY and $1,950 PPPY, respectively, totaling $15,856 PPPY.
Primary and Secondary Outcomes
For patients on HHS "Recommended" antiretroviral regimens, mean MPR was 91.5% ± 14.0 with 73.1% of patients deemed adherent (MPR ≥ 90%).
In univariate analyses, sex (P = 0.009), number of outpatient visits (P = 0.015), cost of inpatient care (P = 0.030), and use of STR (P = 0.002) were significantly associated with MPR ≥ 90% (Table 3 ). There was a higher percentage of men in the adherent group. This group also had higher STR use and fewer outpatient visits. The mean annual inpatient costs were $2,700 in patients who were nonadherent (MPR < 90%), which was more than double the costs for those adherent ($1,343) . The type of health plan, age, number of hospitalizations, and the cost of outpatient care did not correlate significantly with MPR ≥ 90%. 
Selection of Members for Study Cohort
ART= Antiretroviral therapy; HHS = U.S. Department of Health and Human Services; HIV = human immunodeficiency virus; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
In multivariate logistic regression analysis with sex, number of outpatient visits, cost of inpatient care, and use of STR as independent variables, only sex and use of STR maintained statistical significance. Male sex was positively associated with achieving MPR ≥ 90%, P = 0.027 (odds ratio [OR] 1.26, 95% confidence interval [CI] 1.03-1.54). Use of STR was also positively associated with achieving MPR ≥ 90%, P ≤ 0.009 (OR 1.28, 95% CI 1.07-1.54). The number of outpatient visits and cost of inpatient care were not significantly associated with MPR ≥ 90%.
■■ Discussion
This study adds to the current understanding of real-world prescribing of antiretroviral regimens and patient adherence to ART in the U.S. Mid-Atlantic states in recent years. About two thirds of patients who received ART were on an HHSrecommended regimen. Despite differences in study populations, a similar result was found in a study evaluating ART prescribing patterns from the Veterans Affairs Immunologic Case Registry Database. In treatment-naïve veterans, the authors reported that prescribing HHS "preferred" or "alternative" regimens in 2004 was 59.7%. 12 Our study was more recent, patients were commercially insured, HHS "acceptable" as well as "preferred" and "alternative" regimens were considered, and treatment-experienced patients were also included.
For patients on an HHS-recommended ART regimen, 73.1% were at least 90% adherent to therapy. Incomplete adherence may result in drug resistance, virologic failure, morbidity, and decreased survival. 11, 13 Previous research on adherence to ART differs significantly in study methodology, reported rates of ART adherence, as well as the methods used to measure adherence. In a worldwide meta-analysis of 84 observational studies, only 62% of adults with HIV achieved adherence of at least 90% to ART.
14 A pooled analysis of 17 North American studies found that 55% of patients achieved "adequate levels of adherence," which was defined as greater than 80%, 90%, or 95% depending on the study. 15 While recent studies suggest that a lower adherence threshold than 90% may be possible with the availability of more potent NNRTI or boosted PI regimens, [16] [17] [18] there are no definitive data. While the minimum adherence threshold needed is still being discussed, methods to improve patient adherence to ART to achieve a specific threshold have been well researched. Comprehensive, multidisciplinary approaches are required to address varied health care settings and patient populations. [19] [20] Decreasing pill burden by simplifying the ART regimen is one method used to promote ART adherence. 1, 21 STRs that reduce pill burden to as little as 1 pill taken once daily have been associated with improved adherence, reduced hospitalizations, and improved viral suppression. [22] [23] [24] [25] [26] In our study, patients who received STRs were about 1.3 times more likely to be adherent (i.e., MPR ≥ 90%) than patients receiving more than 1 (N = 3,528) antiretroviral product. Several studies showing an association with STR use and improved adherence involved the STR efavirenz/emtricitabline/tenofovir disoproxil fumarate (Atripla), [23] [24] [25] [26] which is a recommended regimen for treatment-naïve patients per the HHS 2011 Guidelines. 1 One study concluded that patients on this fixed-dose STR reported a lower percentage of hospitalizations and emergency room visits. 24 Over 30% of all HIV-infected patients on antiretroviral therapy in the United States already use the STR efavirenz/emtricitabine/tenofovir disoproxil fumarate, and pharmaceutical sales experts predict that it will have the highest antiretroviral sales by 2013. 27 Since the end of the time frame in which we evaluated ART regimens (i.e., 2010), 2 additional STRs have been approved by the U.S. Food and Drug Administration: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera) in 2011 and elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild) in 2012. 28, 29 These regimens may differ from efavirenz/emtricitabline/tenofovir disoproxil fumarate in efficacy, adverse event profile, food restriction requirements, and tablet size, which may also affect adherence.
TABLE 1
Characteristics of Antiretroviral Regimens Categorized by HHS 2011 Guidelines
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Limitations
This retrospective claims analysis has several limitations. Since the study population included only commercially insured patients residing in the Mid-Atlantic region, results may not be representative of Medicare patients or those residing in other regions of the United States. Like other adherence studies that rely on medical and pharmacy claims and lack clinical data, this study was not able to correlate adherence directly with clinical outcomes such as viral load, progression to AIDS, or death. However, previous studies have already established the correlation between clinical outcomes and adherence, as measured by MCO prescription claims data. 10 Without clinical data, this study could not assess the exact reasons for nonadherence, switching, or discontinuation of ART.
This study did not distinguish between treatment-naïve and treatment-experienced patients but used HHS-recommended regimens for treatment-naïve patients to evaluate medication adherence. By choosing to analyze adherence only in HHSrecommended or acceptable regimens, we may have selected a more treatment-naïve population as confirmed by the lower hospitalization rates and higher adherence rates in comparison with previous studies. One large U.S. MCO study found that treatment-experienced patients are at higher risk of nonadherence to ART than treatment-naïve patients. 24 Adherence was evaluated only for the index antiretroviral regimen and did not consider the impact of changing the antiretroviral regimen. Adherence may also be overstated for patients who switched to another ART regimen before finishing their current regimens. MPR was also only calculated for the duration of time when members had existing pharmacy claims, so we did not capture whether patients discontinued therapy completely. Proportion of days covered (PDC) is another method of calculating adherence that has been endorsed by the Pharmacy Quality Alliance and used by the Centers of Medicare and Medicaid Services (CMS) to report ART adherence starting January 2012. 31 PDC accounts for nonpersistence and is a more conservative measurement of adherence than MPR, especially when frequent switching or concomitant therapy with multiple drugs within a class is considered, such as ART. At the time of this study, PDC was not yet used by CMS to report ART adherence. Furthermore, many previous studies have used MPR as a valid measure for adherence to ART and have linked MPR with clinical outcomes such as CD4 counts, increased viral load, and decreased mortality. 6, 10, 11 Future studies using PDC to study adherence may be insightful, especially since CMS is using adherence to ART as a benchmark for MCO performance.
Since the ART regimen was established only within the 120-day period, patients who had medication on hand from stockpiling or patients who received drug samples may have been unintentionally excluded if they had no antiretroviral fill. This could account for why many patients had no claim for antiretroviral medications.
Research has shown that there is a decrease in treatment adherence over time. 3 Like most other adherence studies, this study assumed that adherence was stable and only evaluated adherence for 1 year. An interesting topic for future research 
Univariate Analyses for MPR ≥ 90%
would be to evaluate whether adherence to ART is affected by number of years since HIV diagnosis.
■■ Conclusions
Adherence continues to be a challenge in patients with HIV. More than a quarter of commercially insured patients who were on an HHS-recommended ART regimen failed to achieve an accepted adherence MPR threshold of ≥ 90%. The use of STRs was associated with achieving MPR ≥ 90%, which supports the strategy of reducing pill burden to promote ART adherence.
